Breast cancer treatment options continue to evolve from traditional chemotherapeutic regimens (see table10-13). Margetuximab, a monoclonal antibody in development, has demonstrated promising results in patients with human epidermal growth factor receptor 2 (HER2)—positive breast cancer. Similar to trastu...
In the front-line setting, promising data from a randomized phase 2 trial published last year found that patients withHER2-positive metastatic or recurrent locally advanced breast cancer who received T-DM1 had median progression-free survival of 14.2 months, compared with 9.2 months for participants ...
The use of adjuvant endocrine therapy in the treatment of hormone receptor-positive, early breast cancer has become important in both pre- and postmenopaus... RW Carlson,IC Henderson - 《Breast Cancer Research & Treatment》 被引量: 32发表: 2003年 Phase II, randomized, placebo-controlled study...